HilleVax, Inc. (NASDAQ:HLVX) Short Interest Update

HilleVax, Inc. (NASDAQ:HLVX - Get Free Report) saw a significant decrease in short interest in the month of October. As of October 31st, there was short interest totalling 1,180,000 shares, a decrease of 6.3% from the October 15th total of 1,260,000 shares. Based on an average daily trading volume, of 259,400 shares, the days-to-cover ratio is presently 4.5 days. Currently, 6.4% of the shares of the stock are short sold.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a "neutral" rating and issued a $2.00 target price on shares of HilleVax in a research note on Monday, August 12th. Six analysts have rated the stock with a hold rating, According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $3.00.

HilleVax Stock Performance

HLVX stock remained flat at $1.83 on Monday. 146,248 shares of the company traded hands, compared to its average volume of 432,704. The firm has a market cap of $91.15 million, a PE ratio of -0.59 and a beta of 0.78. The stock's fifty day moving average is $1.82 and its two-hundred day moving average is $5.77. HilleVax has a fifty-two week low of $1.55 and a fifty-two week high of $20.22.

HilleVax (NASDAQ:HLVX - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.10). On average, equities analysts expect that HilleVax will post -2.64 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in HLVX. Braidwell LP acquired a new stake in shares of HilleVax during the third quarter worth approximately $1,873,000. Frazier Life Sciences Management L.P. raised its stake in shares of HilleVax by 8.5% during the second quarter. Frazier Life Sciences Management L.P. now owns 10,617,062 shares of the company's stock worth $153,523,000 after buying an additional 835,590 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of HilleVax in the 2nd quarter valued at $6,960,000. Trium Capital LLP acquired a new position in shares of HilleVax during the 3rd quarter worth about $798,000. Finally, Affinity Asset Advisors LLC acquired a new stake in HilleVax during the 2nd quarter worth $3,844,000. Institutional investors own 86.42% of the company's stock.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.